ArticleJournal of Crohn's & colitis2021
Alteration in Urease-producing Bacteria in the Gut Microbiomes of Patients with Inflammatory Bowel Diseases.
Article in Journal of Crohn's & colitis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Oxygen Tolerance Domestication ofMicroorganisms · 2026Article
- Research advances in the identification of gut keystone bacteria and formulation of suitable dietary intervention strategies for restoring gut homeostasis.NPJ biofilms and microbiomes · 2026Review
- Urease in acetogenicGut microbes · 2025Article
- Design and synthesis of terephthalic dihydrazide analogues as dual inhibitors of glycation and urease.RSC advances · 2025Article
- A Small-Molecule Inhibitor of Gut Bacterial Urease Protects the Host from Liver Injury.ACS chemical biology · 2025Article
- Gut bacteria Prevotellaceae related lithocholic acid metabolism promotes colonic inflammation.Journal of translational medicine · 2025Article
- Targeting CD4+ T cells through gut microbiota: therapeutic potential of traditional Chinese medicine in inflammatory bowel disease.Frontiers in cellular and infection microbiology · 2025Review
- Article
- Component characterization ofFrontiers in cellular and infection microbiology · 2025Article
- Identification of Diagnostic Biomarkers for Compensatory Liver Cirrhosis Based on Gut Microbiota and Urine Metabolomics Analyses.Molecular biotechnology · 2024Article
- The multi-factorial modes of action of urease in the pathogenesis of incontinence associated dermatitis.Skin health and disease · 2024Article
- Shotgun Metagenomic Sequencing Revealed the Prebiotic Potential of a Fruit Juice Drink with Fermentable Fibres in Healthy Humans.Foods (Basel, Switzerland) · 2023Article
- The role of complex interactions between the intestinal flora and host in regulating intestinal homeostasis and inflammatory bowel disease.Frontiers in microbiology · 2023Review
Corrections and comments
- Expression of concern · 2022-01-24Civil Proceedings · Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Legal Reasons and/or Threats · · See also: https://doi.org/10.1093/ecco-jcc/jjab225 Journal was previously published by Elsevier until 2015.
- Commented on by
- Erratum issuedCorrection.2023
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
aimsBacterial urease is a major virulence factor of human pathogens, and murine models have shown that it can contribute to the pathogenesis of inflammatory bowel diseases [IBD].
methodsThe distribution of urease-producing bacteria in IBD was assessed using public faecal metagenomic data from various cohorts, including non-IBD controls [n = 55], patients with Crohn's disease [n = 291] or ulcerative colitis [n = 214], and patients with a pouch [n = 53]. The ureA gene and the taxonomic markers gyrA, rpoB, and recA were used to estimate the percentage of urease producers in each sample.
resultsLevels of urease producers in patients with IBD and non-IBD controls were comparable. In non-IBD controls and most IBD patients, urease producers were primarily acetate-producing genera such as Blautia and Ruminococcus. A shift in the type of the dominant urease producers towards Proteobacteria and Bacilli was observed in a subset of all IBD subtypes, which correlated with faecal calprotectin levels in one cohort. Some patients with IBD had no detectable urease producers. In patients with a pouch, the probiotic-associated species Streptococcus thermophilus was more common as a main urease producer than in other IBD phenotypes, and it generally did not co-occur with other Bacilli or with Proteobacteria.
conclusionsUnlike all non-IBD controls, patients with IBD often showed a shift towards Bacilli or Proteobacteria or a complete loss of urease production. Probiotics containing the species S. thermophilus may have a protective effect against colonisation by undesirable urease-producing bacteria in a subset of patients with a pouch.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.